Joele Frank is handling media for Alder BioPharmaceuticals, which is focused on the development and commercialization of migraine treatments, in its $2B sale to Denmark’s Lundbeck.
 |
The Danish company is offering $18 per-share for Alder, a 79 percent premium over its Sept. 13 closing price on the NASDAQ.
The owner of a portfolio of brain disease therapies will ante up another $2 per-share, if European regulators approve Alder’s next-generation eptinezumab migraine drug. The US Food & Drug Administration is on track to okay the treatment in February.
An estimated 135M people experience migraines annually. They are characterized by recurrent episodes of moderate to severe headaches accompanied by nausea, vomiting and sensitivity to sound and light.
CEO Deborah Dunsire called Alder an excellent strategic fit that leverages Lundbeck’s “specialized commercial expertise in delivering medicines for brain diseases.”
The transaction is expected to wrap up by yearend.
Joele Frank, Wilkinson Brimmer Katcher’s Andy Brimmer, Aura Reinhard and Tanner Kaufman represent Alder, while Stern Investor Relations’ Sarah McCabe works Wall Street for the Bothell, WA-based biopharmaceutical company.
Joele Frank handles Crinetics Pharmaceuticals as the specialist for treatments for endocrine diseases agrees to get acquired by Vertex Pharmaceuticals in a deal pegged at $8.8B.
Teneo represents Honeywell spin-off Solstice Advanced Materials as it buys Collected Strategies client Element Solutions in a deal pegged at $14.5B.
Dallas-based Throughline Global Advisors advised Principal Mineral as it acquired Isola Group, maker of copper-clad laminates used in printed circuit boards.
oele Frank works for satellite operator Iridium Communications as it gets acquired by space company Rocket Lab in a deal worth $8B.
Uber’s Mike Lucarelli is moving to NXP Semiconductors as senior VP-investor relations.
